** Shares of cancer testing services company NeoGenomics NEO.O fall ~15% to $12.2 in morning trade
** NEO posts Q4 revenue of $172 million, missing analysts' estimates of $173.2 million, according to data compiled by LSEG
** Company reports adj. Q4 profit of 4 cents/shr, compared to analysts' estimates of 3 cents/shr
** Company forecasts net loss of $85 million to $76 million for 2025
** NEO also forecasts 2025 revenue in the range of $735 million to $745 million
** Stock down 3.2% over the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。